Regional Burden of Enlarged Perivascular Spaces and Cognition and Neuropsychiatric Symptoms in Drug-Naive Patients With Parkinson Disease

Enlarged perivascular space in the temporal lobe as a prognostic marker in temporal lobe epilepsy with hippocampal sclerosis

OBJECTIVE

This study was undertaken to investigate the regional burden of enlarged perivascular spaces (EPVSs) in patients with temporal lobe epilepsy with hippocampal sclerosis (TLE-HS) and explore its prognostic relevance.

METHODS

In this retrospective observational study, EPVSs in the temporal lobe (T-EPVS), centrum semiovale (CS-EPVS), basal ganglia (BG-EPVS), midbrain, and hippocampus were visually rated in 68 treatment-naïve patients with TLE-HS. Regional EPVS burden was dichotomized into high and low degrees (cutoff: >10 for BG-EPVS/T-EPVS; >20 for CS-EPVS). Cox proportional hazards models were used to determine the potential predictors of seizure freedom (SF; no seizure for >1 year) and delayed SF (SF achieved >6 months after initiating antiseizure medication [ASM]). Multivariate logistic regression using stepwise variable selection based on the Akaike information criterion was performed to investigate whether EPVS burden was associated with medical refractoriness (never achieving SF).

RESULTS

Of the 68 patients, 20 were classified into the refractory group (29.4%). The high T-EPVS group had an older epilepsy onset (37.3 ± 12.3 vs. 26.5 ± 13.0 years, p = .005), higher pretreatment seizure density (median = 12.0, interquartile range [IQR] = 5.0-20.0 vs. 4.0, IQR = 2.0-10.5, p = .008), and lower focal to bilateral tonic-clonic seizure prevalence (13.3% vs. 73.6%, p < .001) than the low T-EPVS group. High T-EPVS burden (odds ratio [OR] = 10.908, 95% confidence interval [CI] = 1.895-62.789) was an independent predictor of medial refractoriness, along with female sex (OR = 12.906, 95% CI = 2.214-75.220) and ASM treatment duration (OR = .985, 95% CI = .971-.999). The low T-EPVS group had higher probability of achieving delayed SF than the high T-EPVS group (pLog-rank = .030, pCox regression = .038), whereas the probability of achieving SF was comparable between the two groups (pLog-rank = .053, pCox regression = .146).

SIGNIFICANCE

Increased T-EPVS burden may serve as an imaging marker of unfavorable prognosis in patients with TLE-HS, underscoring the potential role of perivascular dysfunction in diminished ASM response.

Cerebral Small Vessel Disease Outperforms Brain Atrophy as an Imaging Biomarker in Diabetic Retinopathy

AIM

This study aimed to examine microvascular lesions and neurodegenerative changes in diabetic retinopathy (DR) compared to type 2 diabetes mellitus (T2DM) without DR (NDR) using structural MRI and to explore their associations with DR.

METHODS

243 patients with NDR and 122 patients with DR were included. Participants underwent conventional brain MRI scans, clinical measurements, and fundus examinations. Cerebral small vessel disease (CSVD) imaging parameters were obtained using AI-based software, manually verified, and corrected for accuracy. Volumes of major cortical and subcortical regions representing neurodegeneration were assessed using automated brain segmentation and quantitative techniques. Statistical analysis included T-test, chi-square test, Mann-Whitney U test, multivariate analysis of variance (MANCOVA), multivariate logistic regression, area under the receiver operating characteristic curve (AUC), and Delong test.

RESULTS

DR group exhibited significant differences in 11 CSVD features. Meanwhile, DR showed an atrophy trend in the frontal cortex, occipital cortex, and subcortical gray matter (GM) compared to NDR. After adjustment, DR patients exhibited greater perivascular spaces (PVS) numbers in the parietal lobe (OR = 1.394) and deep brain regions (OR = 1.066), greater dilated perivascular spaces (DPVS) numbers in the left basal ganglia (OR = 2.006), greater small subcortical infarcts (SSI) numbers in the right hemisphere (OR = 3.104), and decreased left frontal PVS (OR = 0.824), total left DPVS (OR = 0.714), and frontal cortex volume (OR = 0.959) compared to NDR. Further, the CSVD model showed a larger AUC (0.823, 95% CI: 0.781-0.866) than the brain atrophy model (AUC = 0.757, 95% CI: 0.706-0.808).

CONCLUSION

Microvascular and neurodegeneration are significantly associated with DR. CSVD is a better imaging biomarker for DR than brain atrophy.

Neurotransmitter imbalance, glutathione depletion and concomitant susceptibility increase in Parkinson's disease

BACKGROUND

Emerging insights into the pathophysiology of Parkinson's disease (PD) underscore the involvement of dysregulated neurotransmission, iron accumulation and oxidative stress. Nonetheless, the excitatory and inhibitory neurometabolites, the antioxidant glutathione (GSH), and magnetic susceptibility are seldom studied together in the clinical PD literature.

METHODS

We acquired MEGA-PRESS and multi-echo gradient echo sequences from 60 PD patients and 47 healthy controls (HCs). Magnetic resonance spectroscopy voxels were respectively positioned in the midbrain to quantify neurotransmitter including γ-aminobutyric acid (GABA) and glutamate plus glutamine, and in the left striatum to estimate GSH levels. Group differences in metabolite levels normalized to total creatine (Cr) and their clinical relevance were determined. Furthermore, relationships among GSH levels, neurotransmitter estimates and susceptibility values were explored in both PD patients and HCs.

RESULTS

PD patients exhibited reduced midbrain GABA levels (P = 0.034, PFDR = 0.136), diminished GSH in the left striatum (P = 0.032, PFDR = 0.096), and increased susceptibility values in the substantia nigra (PFDR < 0.001). Mesencephalic choline levels were correlated with the severity of rapid eye movement sleep behavior disorders symptoms, whereas striatal N-acetylaspartate levels were linked to Hoehn-Yahr stage and motor symptom severity. Notably, the disruption of associations between striatal GSH levels and susceptibility values in globus pallidus, as well as midbrain GABA levels, were evident in PD.

CONCLUSIONS

These findings offer compelling evidence for metabolic dysregulation in PD, characterized by a concomitant reduction in GABA and GSH levels, alongside iron deposition.